To compare the global clinical response of posaconazole (POS) compared to voriconazole (VOR) in the first line treatment of invasive aspergillosis (IA) at Week 6 in those subjects with proven or probable IA. The hypothesis to be tested is that the proportion of subjects achieving the global clinical response at Week 6 in the POS treatment group is noninferior to that in the VOR treatment group.
POS was shown to be effective in an open label, externally controlled salvage therapy trial of 107 patients with proven/probable aspergillosis.